HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Brian I Rini Selected Research

Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

2/2022Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
1/2021Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.
1/2021Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
7/2020Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
1/2020Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting.
1/2019Immunotherapy for renal cell carcinoma.
1/2018Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
1/2018Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
11/2017Treatment of renal cell carcinoma: Current status and future directions.
7/2017The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Brian I Rini Research Topics

Disease

265Renal Cell Carcinoma (Grawitz Tumor)
10/2022 - 04/2002
136Neoplasms (Cancer)
10/2022 - 02/2002
27Disease Progression
10/2022 - 03/2004
24Hypertension (High Blood Pressure)
12/2020 - 03/2006
21Prostatic Neoplasms (Prostate Cancer)
11/2021 - 02/2002
19Fatigue
10/2021 - 03/2006
18Neoplasm Metastasis (Metastasis)
01/2021 - 06/2004
12Kidney Neoplasms (Kidney Cancer)
10/2022 - 06/2004
11COVID-19
12/2021 - 01/2020
9Hypoxia (Hypoxemia)
01/2019 - 04/2004
6Carcinoma (Carcinomatosis)
12/2018 - 12/2011
5Hand-Foot Syndrome
10/2019 - 01/2012
5Exanthema (Rash)
10/2016 - 03/2006
4Proteinuria
01/2018 - 11/2008
4Neutropenia
11/2016 - 06/2006
3Thrombosis (Thrombus)
01/2019 - 02/2011
3Edema (Dropsy)
01/2018 - 12/2015
3Anemia
01/2018 - 06/2006
3Diarrhea
01/2018 - 01/2012
3Melanoma (Melanoma, Malignant)
12/2017 - 11/2011
3Hyperglycemia
10/2016 - 12/2009
3Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
10/2016 - 01/2007
2Infections
12/2021 - 11/2021
2Pneumonia (Pneumonitis)
05/2020 - 03/2014
2Necrosis
01/2020 - 04/2014
2Mucositis
10/2019 - 12/2010
2Urinary Bladder Neoplasms (Bladder Cancer)
01/2019 - 01/2018
2Clear-cell metastatic renal cell carcinoma
01/2018 - 05/2013

Drug/Important Bio-Agent (IBA)

89Sunitinib (Sutent)FDA Link
10/2022 - 12/2005
71Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2022 - 04/2004
38Axitinib (AG 013736)IBA
10/2022 - 12/2005
28Bevacizumab (Avastin)FDA Link
02/2022 - 04/2004
26NivolumabIBA
01/2022 - 05/2015
24Immune Checkpoint InhibitorsIBA
10/2022 - 09/2016
24Sorafenib (BAY 43-9006)FDA Link
10/2021 - 03/2006
21Biomarkers (Surrogate Marker)IBA
10/2022 - 07/2007
21Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
10/2022 - 01/2006
19IpilimumabIBA
01/2022 - 03/2007
16Tyrosine Kinase InhibitorsIBA
10/2021 - 02/2007
11CytokinesIBA
10/2019 - 05/2002
10atezolizumabIBA
02/2022 - 01/2018
10TOR Serine-Threonine KinasesIBA
10/2016 - 12/2005
10Interferon-alpha (Interferon Alfa)IBA
03/2014 - 04/2004
9Biological ProductsIBA
01/2022 - 05/2002
9Pharmaceutical PreparationsIBA
01/2021 - 06/2004
8AndrogensIBA
11/2021 - 05/2002
7pembrolizumabIBA
10/2022 - 01/2019
7Hormones (Hormone)IBA
01/2020 - 02/2002
7Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
10/2019 - 01/2003
7AntigensIBA
11/2011 - 02/2002
6Proteins (Proteins, Gene)FDA Link
01/2021 - 07/2006
6pazopanibFDA Link
03/2019 - 07/2012
6temsirolimusFDA Link
03/2014 - 09/2006
6Interleukin-2 (IL2)IBA
01/2012 - 05/2002
5B7-H1 AntigenIBA
01/2022 - 01/2018
5Angiogenesis InhibitorsIBA
03/2020 - 10/2006
5VaccinesIBA
02/2017 - 02/2002
5EverolimusFDA Link
10/2016 - 09/2006
5Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
12/2007 - 01/2006
5Prostate-Specific Antigen (Semenogelase)IBA
03/2007 - 01/2003
4avelumabIBA
10/2022 - 01/2018
4LigandsIBA
02/2022 - 11/2011
4EnzymesIBA
01/2022 - 09/2006
4Hydroxychloroquine (Plaquenil)FDA LinkGeneric
01/2021 - 01/2020
4Peptides (Polypeptides)IBA
02/2017 - 02/2009
4Imatinib Mesylate (Gleevec)FDA Link
10/2016 - 10/2006
4MTOR InhibitorsIBA
06/2016 - 10/2008
4Phosphotransferases (Kinase)IBA
02/2012 - 05/2006
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
02/2022 - 06/2006
3tivozanibIBA
10/2021 - 01/2020
3Alanine Transaminase (SGPT)IBA
12/2020 - 01/2018
3Monoclonal AntibodiesIBA
07/2020 - 02/2007
3Lipase (Acid Lipase)FDA Link
10/2019 - 06/2006
3ChemokinesIBA
10/2019 - 11/2011
3AmylasesFDA Link
10/2019 - 12/2015
3Interleukin-8 (Interleukin 8)IBA
05/2017 - 02/2010
3InterferonsIBA
01/2012 - 02/2009
3Fluorouracil (Carac)FDA LinkGeneric
09/2008 - 10/2002
3sipuleucel-T (APC8015)FDA Link
07/2006 - 02/2002
3prostatic acid phosphataseIBA
07/2006 - 02/2002
2Adrenal Cortex Hormones (Corticosteroids)IBA
10/2020 - 03/2007
2Immunoglobulin G (IgG)IBA
05/2020 - 01/2018
2Transcription Factors (Transcription Factor)IBA
01/2020 - 01/2019
2PT2385IBA
01/2020 - 01/2018
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
10/2019 - 01/2006
2human ALK1-Fc fusion proteinIBA
01/2019 - 07/2017
2Cisplatin (Platino)FDA LinkGeneric
01/2018 - 01/2018
2Docetaxel (Taxotere)FDA Link
01/2018 - 06/2007
2Fatty Acids (Saturated Fatty Acids)IBA
11/2017 - 10/2016

Therapy/Procedure

167Therapeutics
10/2022 - 02/2002
26Nephrectomy
01/2022 - 06/2004
25Immunotherapy
11/2021 - 06/2003
8Aftercare (After-Treatment)
12/2021 - 12/2006
6Castration
01/2020 - 10/2002
6Drug Therapy (Chemotherapy)
03/2018 - 04/2002
4Neoadjuvant Therapy
01/2019 - 01/2018
4Molecular Targeted Therapy
01/2018 - 01/2007
3Radiotherapy
03/2018 - 01/2003
2Drug Tapering
01/2018 - 03/2015
2Cystectomy
01/2018 - 01/2018